Home › Squamous Cell Carcinoma › California
Pag-aaral pangklinika para sa Squamous Cell Carcinoma sa California
13 pag-aaral para sa Squamous Cell Carcinoma ang naghahanap ng mga kalahok sa mga site sa California.
Mga Lungsod sa California
Opisyal na teksto ng pag-aaral (English)
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Oncura Health, Glendale
- UC San Diego Health - Moores Cancer Center, La Jolla
- California Research Institute, Los Angeles
- at 4 pa
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT04198766JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- City of Hope, Duarte
- University of California at San Diego Moores Cancer Center, La Jolla
- UCLA Hematology Oncology, Los Angeles
- at 1 pa
Nagre-recruitPhase 3
Edad 60 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT04892173Basal Cell Carcinoma Chemoprevention Trial
- VA Long Beach Healthcare System, Long Beach, CA, Long Beach
- VA San Diego Healthcare System, San Diego, CA, San Diego
Nagre-recruitPhase 3Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT05212246Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
- City of Hope Medical Center, Duarte
- Los Angeles Cancer Network (LACN), Los Angeles
- Medical Oncology Associates of San Diego, San Diego
- at 1 pa
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 28, 2026 · NCT06295731Intratumoral N17350 in Advanced Solid Tumors
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
- Scripps Clinic Torrey Pines - La Jolla, San Diego
- at 1 pa
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 21, 2026 · NCT07339176Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Moores Cancer Center UC San Diego Health, La Jolla
- Keck School of Medicine of USC, Los Angeles
- UCLA, Los Angeles
- at 1 pa
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 6, 2026 · NCT04429542Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Precision NextGen Oncology, Beverly Hills
- OPN Healthcare, Inc, Glendale
- University of Southern California, Los Angeles
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06047379Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
- Stanford University, Stanford
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT06736379A Study of IDP-001 in Advanced or Metastatic Solid Tumors
- START Los Angeles, Los Angeles
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT07602842Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Nagre-recruitMaagang Phase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT07628634Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
- Stanford University, Redwood City
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 20, 2026 · NCT06731933A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- University of California Los Angeles, Los Angeles
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 9, 2026 · NCT06064877A Study of VET3-TGI in Patients With Solid Tumors
- USC/Norris Comprehensive Cancer Center, Los Angeles
- UC Irvine Health, Orange
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 7, 2026 · NCT06444815Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.